Approximately a quarter of patients suffering from prostate cancer exhibit mutations in their DNA repair genes. Joaquin Mateo, MD, from the Institute of Cancer Research and The Royal Marsden, London, UK, discusses his work which examines these mutations. Dr Mateo also talks about two treatments which are currently being examined for their beneficial value in prostate cancer patients. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) held in Madrid, Spain.